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Abstract: 
Scientific novelty is important during the pandemic due to its critical role in generating new 
vaccines. Parachuting collaboration and international collaboration are two crucial channels to 
expand teams’ search activities for a broader scope of resources required to address the global 
challenge. Our analysis of 58,728 coronavirus papers suggests that scientific novelty measured 
by the BioBERT model that is pre-trained on 29 million PubMed articles, and parachuting 
collaboration dramatically increased after the outbreak of COVID-19, while international 
collaboration witnessed a sudden decrease. During the COVID-19, papers with more 
parachuting collaboration and internationally collaborative papers are predicted to be more 
novel. The findings suggest the necessity of reaching out for distant resources, and the 
importance of maintaining a collaborative scientific community beyond established networks 
and nationalism during a pandemic. 
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Newton developed the basis for his groundbreaking work during the Great Plague, having 
far-reaching impacts on classical physics and many other domains. The experience of Newton 
has been raised repeatedly in the 2020 context of the global COVID-19 pandemic. Will 
scientists be more novel during the pandemic like Newton? Truly breakthrough ideas rarely 
occur overnight, while novelty is sometimes sparked by extreme time pressure and urgent needs. 
These two points of views provide contrasting possibilities regarding the association between 
scientific novelty and the disruption of a pandemic.  
As the seed of innovation (1), scientific novelty could be considered the recombination of 
prior knowledge components in an unfamiliar or atypical fashion (2-4). Novel research is more 
likely to advance the frontier of scientific discoveries, and becomes more important than ever 
during the pandemic because of the urgent need for new vaccines for public health.  
Scientific teams’ search activities that are important for scientific novelty might be 
reshaped during the pandemic, while it is unknown whether parachuting collaboration and 
international collaboration that are closely associated with teams’ “search space” are 
accelerated or reversed. During the pandemic, the lack of access to resources that might be only 
available in special localities motivates scientific teams to overcome the constraints of 
localized search by collaborating outside their established networks and across national borders 
(5). On the other hand, the novel global challenge and the urgent need for effective vaccines 
might encourage the adjustment of team assembly towards effective teamwork that produces 
new ideas by including newcomers beyond team members’ pre-existing relationships and 
reaching international networks (6-8). Given the importance of international collaboration and 
parachuting collaboration measured by the faction of team members without prior collaboration 
in a team, in reaching out for distant resources and producing novel knowledge, these two types 
of collaboration patterns might increase during the pandemic. However, the urgent pandemic 
situation might lead to a reduction in search and outreach (5) and increased costs of 
communication and coordination, which thus causes a decline in these two collaboration 
patterns.  
A disaster of global scale, as of 13 September 2020, COVID-19 has infected at least 28.6 
million people, proving deadly to 917,000 individuals.1 We use this unexpected outbreak as a 
natural experiment and find that (1) coronavirus research became far more novel during the 
pandemic; and (2) scientific teams involved more parachuting collaboration defined as 
collaboration between two authors without prior collaboration, while international 
collaboration suddenly decreased; and (3) during the pandemic, papers with a higher 
parachuting ratio, and internationally collaborative papers are predicted to be more novel. 
Data and methods 
Building on the “knowledge recombination” theory (4) and the combinatorial perspective 
of novelty (3, 9), we assess papers’ scientific novelty by quantifying how extraordinary a 
combination of bio-entities is in a coronavirus-related paper using BioBERT (Bidirectional 
Encoder Representations from Transformers for Biomedical Text Mining) (10), a language 
model that is pre-trained on 29 million PubMed articles. In medicine, represented by bio-
 
1 https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?. 
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entities (e.g., drug, disease, and gene) in publications (11), knowledge is combined to form new 
ideas; especially uncommon combinations of bio-entities form especially novel ideas (12). In 
this study, when the distance between two bio-entities is in the upper 10th percentile in the 
distribution of the distance of all entity pairs extracted from 58,728 coronavirus research 
articles, the combination of two bio-entities is considered novel. Paper’s novelty score is 
measured by the fraction of novel entity combinations extracted from the paper, ranging 
between 0 and 1. The higher paper’s novelty score, the more novel entity combinations in the 
paper.2 The framework and an illustrative example of calculating papers’ novelty scores are 
shown in Fig.S9 in the Supplementary Material. The details of quantifying papers’ novelty 
regarding entity combinations are shown in Measuring Scientific Novelty of Papers in the 
Supplementary Material. 
We treat the outbreak of COVID-19 as a natural experiment to explore how scientific 
novelty, parachuting collaboration and international collaboration evolve during such a disaster. 
We use a difference in differences (DID) approach based on 11,678 coronavirus articles 
published from January 2018 to April 2020 by the top 50 prolific countries ranked by the 
number of coronavirus papers published during the study period. The details of the data source 
and sample selection are shown in the section of Data and Sample in the Supplementary 
Material. We examine the association between monthly change in scientific novelty, 
parachuting collaboration ratio and international collaboration of coronavirus papers by 50 
sampled countries and their status as a confirmed COVID-19 infection site from January 2018 
to April 2020 by month. Variables and the DID strategy are specifically reported in the sections 
of Variables and Method: a Difference in Differences Strategy, respectively in the 
Supplementary Material. 
Results 
Novelty of coronavirus research after COVID-19 
Our findings suggest that coronavirus research has become more novel since the outbreak 
of the COVID-19. After 2019, the year of the COVID-19 outbreak, there is a dramatic increase 
in the average novelty score of global coronavirus research relative to the earlier years (see 
Fig.1(A)). Since the global first COVID-19 case was officially confirmed in December 2019, 
the average novelty score of global coronavirus papers sharply went up (see Fig.1(B)).  
The results of the DID regression show that “treated” countries (i.e., countries with an 
infection) have a 0.038 (p<0.01) higher novelty score than “untreated” countries (i.e., countries 
without infection)—this is an increase of 28.51% standard deviation (see column 1 in Table S8 
in the Supplementary Material). The estimated dynamic impact of a COVID-19 outbreak in a 
 
2 Creative ideas could be reflected by two dimensions, namely usefulness and novelty. Novelty is the key distinguish feature 
of creativity beyond ideas that are well conceived. The notion that considers novelty as a process of recombination has bene 
shown as valuable, while some criticized that many unusual configurations might be worthless. In this study, we only consider 
the aspect of novel recombination of knowledge as for recently published papers, the time is too short to receive citations from 
subsequent research. We conduct analyses of the relationship between coronavirus papers’ novelty and citation, and do not 
found that papers’ novelty is significantly negatively related to citations papers gained, which suggests that at least, novel 
papers according to our definition, are not useless papers. The details of the relationship between papers’ novelty score and 
citations paper received are illustrated in the section of The Relationship between Papers’ Novelty Scores/Teams’ 
Characteristics and Citations in the Supplementary Material. 
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country on the country’s scientific novelty score of coronavirus literature is shown in Fig.2(A), 
which illustrates a jump in countries’ average novelty scores in the first month (i.e., t+1 where 
t refers to the month the first COVID-19 case was confirmed in a country) after the first 
occurrence of COVID-19 case in a country, while there is no significant difference between 
treated and untreated countries before the first COVID-19 case in the country. The regression 
results show that more COVID-19 cases and deaths in a month predict a higher scientific 
novelty (see Table S9 in the Supplementary Material), suggesting that the increased scientific 
novelty might be associated with the severity of the local outbreak. 
Collaboration of coronavirus papers after COVID-19 
After the global first COVID-19 case, Fig.1(B) presents a sudden decrease in global 
coronavirus papers’ international collaboration ratio. DID estimates suggest that countries’ 
parachuting collaboration ratio increased by 3.1% (coefficient: 0.031, p < 0.01 in column 3 in 
Table S8 in the Supplementary Material) after the report of the first COVID-19 case in a country. 
This suggests that after the first case confirmed in the country, more parachuting collaboration 
is found in coronavirus research for the country. We further find that country’s proportion of 
internationally collaborative papers in coronavirus research shrunk by 9.2% (coefficient: -
0.092, p < 0.01 in column 5 in Table S8 in the Supplementary Material) after the occurrence of 
the first COVID-19 case in a country. The dynamic impact of the first COVID-19 case in the 
country on its average parachuting collaboration and international collaboration ratio is 
estimated in columns 4 and 6 in Table S8 in the Supplementary Material, respectively, and is 
illustrated in Fig.2 (B) and (C).  
We also observe a sudden change in scientific novelty, international and parachuting 
collaboration ratio around the year of the outbreak of SARS, with the same direction we find 
during the COVID-19 (see Fig.1(A)). 
The relationship between novelty and collaboration during COVID-19. 
Figure.S10(A) in the Supplementary Material illustrates papers’ estimated novelty score 
estimated by a regression model including interaction terms between papers’ parachuting 
collaboration ratio or international collaboration and the occurrence of the first global COVID-
19 case. It suggests that before COVID-19, papers’ parachuting collaboration ratio is 
significantly negatively related to papers’ novelty scores. However, this relationship turns 
significantly positive for papers published during the COVID-19. This pattern holds for the 
association between papers’ international collaboration and novelty scores (Fig. S10(B) in the 
Supplementary Material). The subsample analyses also confirm these findings (see columns 1 
and 2 in Table S10 in the Supplementary Material). The methods to conduct sub-sample 
analyses and regression analyses including the interaction terms between papers’ parachuting 
collaboration ratio/international collaboration and the occurrence of the first global COVID-19 
case are shown in Sub-sample Analyses and Regression including Interaction Terms in the 
Supplementary Material.  
Discussion 
Our results show that in the initial period following a coronavirus outbreak, scientific 
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novelty dramatically increased, which suggests scientists’ efforts to try novel recombination of 
existing knowledge to combat this global pandemic. The fraction of parachuting collaboration, 
i.e., collaboration between team members without prior collaboration, in the scientific teams 
of coronavirus research grew, while the proportion of internationally collaborative papers 
sharply decreased.  
In the pre-COVID19 period, parachuting collaboration is significantly negatively 
associated with paper’s novelty score, while this relationship turns significantly positively 
related to paper’s novelty during the pandemic. Teams’ characteristics are important 
determinants of team efficiency and the production of novel knowledge. Parachuting 
collaboration, the foil of repeat collaboration, entails both advantages and costs that influence 
teams’ novelty, making its contribution to scientific novelty not straightforward. Unlike repeat 
collaboration, parachuting collaboration involves more search, coordination and innovation 
costs, less risk-sharing, trust and reciprocity, which might dampen scientific novelty (5, 6, 13). 
However, parachuting collaboration allows pooling together a broader scope of information, 
data and resources outside the preexisting relationships and conflicts that might improve 
scientific novelty (7, 14). During the pandemic, papers produced by teams with a larger 
proportion of parachuting collaboration are more novel, which suggests greater importance of 
a broader scope of search activities and quick access to non-local information that is only 
available outside teams’ pre-existing networks in tackling global challenges timely.  
We find that internationally collaborative papers are more novel than their counterparts 
during the pandemic. International collaboration trends to produce more conventional 
knowledge combinations since transaction costs and communication barriers to international 
collaboration might hinder novelty (8). This is consistent with what we find in the normal 
science period. However, during COVID-19, producing novel knowledge might require 
collaborative efforts across national borders that pool global resources more than ever. The best 
example is the discovery of the causative agent of SARS, a result of close international 
collaboration among 13 laboratories from 10 countries.3 
Most science of science studies assumes that the research system operates with institutional 
stability, in the framework of “normal science” (15). With rapidly developing globalization and 
the increasing complexity of economic, societal, political and environmental issues, the 
traditional perception of normal science is no longer sufficient to address issues or problems in 
the scientific community. Local and even global research systems could be immediately 
influenced by exogenous and unexpected events. This study provides evidence on how science 
progresses differently during a pandemic from a normal science period.   
 
3 https://news.un.org/en/story/2003/04/64992-who-announces-discovery-virus-causes-sars 
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Fig. 1. The trend of average novelty score and parachuting/international collaboration ratio for global 
coronavirus research. The left vertical axis in each sub-figure indicates the novelty score of papers and the 
right one refers to parachuting/international collaboration ratio. In sub-figure B, the study period is from 
January 2018 to April 2020, with a total of 28 months. The global first COVID-19 case is officially reported 
in the 24th month, December 2019; the number in the X-axis indicates n month since the start of the study 
period (Jan 2018). The solid and dash lines indicate the actual value and the predicted value of variables 
based on the trend of variables before December 2019, respectively. The purple and blue dash lines indicate 
the time series prediction of parachuting/international collaboration ratio, respectively. The orange dash line 
refers to the predicted values for novelty score after a linear regression where country’s monthly novelty 
score is the dependent variable, and explanatory variables include country’s parachuting/international 
collaboration ratio, team size and productivity, with all values of explanatory variables in and after December 
2019 replaced by their time-series predicted values. In this way, we construct a counterfactual-like 
framework where the novelty score evolves if COVID-19 did not occur, in other words, all explanatory 
variables follow their trends in pre-COVID19 period after December 2019. The shaded areas represent upper 
and lower bounds of 95% CIs. 
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Fig. 2. The DID estimates of the relationship between the occurrence of the first case of COVID-19 in 
the country and countries’ average novelty scores, parachuting collaboration ratio and international 
collaboration ratio in a month. T-n indicates n month(s) before the month (t0) when the first COVID-19 
case was confirmed in the country, and t+n indicates n month(s) after t0. ***, ** and * represent significance 
at the 1%, 5%, and 10% level. The shaded areas represent upper and lower bounds of 95% CIs. 
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Data and Sample 
Data Source 
Two major datasets are used in this study, with one including publication data on 
coronavirus research that is used to measure an individual paper’s scientific novelty and 
capture authors’ country information, and another including country-by-country patient 
data about COVID-19 that is used to identify the timing when the first COVID-19 case 
is confirmed in a country. 
Publication Data on Coronavirus 
Publication data on coronavirus research is collected from the COVID-19 Open 
Research Dataset (hereafter CORD-19)4 that covers 58,728 research articles about 
COVID-19 and related historical coronaviruses, such as SARS and MERS, that were 
published during the 1951-April 2020 period. This dataset includes title, abstract, 
author name, DOI, PubMed ID, and publication date. This dataset is constructed by the 
Allen Institute for AI and other leading research groups to facilitate researchers to 
discover relevant information more quickly from the literature. CORD-19 papers are 
sourced from PubMed Central, bioRxiv and medRxiv, with titles, abstracts or full text 
including the following keywords:  
“COVID-19” OR “Coronavirus” OR “Corona virus” OR “2019-nCoV” OR 
“SARS CoV” OR “MERS-CoV” OR “Severe Acute Respiratory Syndrome” OR 
“Middle East Respiratory Syndrome”.  
CORD-19 dataset has been recently used in analyzing coronaviruses literature (1-
4), and is viewed as a reliable data source to map coronavirus-related research. The 
distribution of papers per year in CORD-19 is illustrated in Fig. S1(A), which indicates 
a sudden growth of papers in the years of significant pandemics.  
Identifying Country Information for Authors in CORD-19 Dataset 
We identify authors’ country information based on authors’ address information 
provided by CORD-19 dataset and the 29 million PubMed dataset that covers 1800-
2020 with author names disambiguated (5). Based on DOI and PubMed ID provided in 
CORD-19 dataset, 51,726 CORD-19 papers are linked to their versions in the PubMed 
dataset where all author names have been disambiguated and thus the following 
information of CORD-19 papers was obtained: authors’ unique identifiers and authors’ 
address information. Authors' unique identifiers allow us to know whether authors in a 
paper have collaborated in the past according to their publications records in the 
PubMed database, which enables us to identify parachuting collaboration. Authors’ 
affiliation information helps us to identify country names from authors’ address 
information in each article by manually merging variations (e.g., ISO two-letter or 
three-letter country codes, alternative country names, country names in other languages, 
 
4 https://www.kaggle.com/allen-institute-for-ai/CORD-19-research-challenge. This dataset was 
downloaded on May 8, 2020. 
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and country names with typos) of country names into the same country. Finally, 
standard country names corresponding to authors’ locations in 45,470 CORD- papers 
are found. 17 Papers with the number of authors larger than 100 have been removed as 
the inclusion of papers with hyper-authorship might make the calculation of team 
variables biased because of the outliers.  
Patient Data on COVID-19 
Additionally, we use the patient data on COVID-19 derived from the website of 
Our World in Data that covers 211 countries from December 2019 to 2020 May,5 to 
capture the timing when the first COVID-19 case is officially confirmed,6 and the daily 
number of new COVID-19 cases and deaths in each sampled country during the 
December 2019- April 2020 period. The 50 sampled countries account for 92.85% of 
cases and 97.24% of deaths related to COVID-19 from December 2019 to April 2020. 
The distribution of COVID-19 cases and deaths in each month is illustrated in Fig. S2. 
 
Sample Selection 
The final dataset used for the regression analysis includes 11,678 research articles 
published from January 2018 to April 2020 by the top 50 prolific countries that are 
ranked by the number of coronavirus-related papers published during the study period.  
The research goal of this study is to compare monthly changes in countries’ scientific 
novelty before and during the COVID-19. The period of 2018 Janurary-2019 November 
is considered a sufficient time window to present scientific novelty in the pre-COVID-
19 period (1). To measure the country’s productivity, we use a full counting method (6) 
based on the authors’ address information. For example, for a paper authored by two 
scientists with Chinese affiliations, one scientist with a US affiliation and three 
scientists with UK affiliations, China, the US and the UK get two, one and three papers, 
respectively.7 Hence, overall six publications are allocated to these three countries. 
More than 108 countries published coronavirus research during the study period, among 
which the top 50 prolific countries are selected as the sampled countries. The variable 
that measures the monthly average novelty score for countries that did not publish any 
or publish very few coronavirus papers would be missing. The observations that have 
a missing value for any one of the variables used in the regression model would be 
dropped by Stata. This is why we limit the regression analysis to the top 50 most prolific 
countries, which account for more than 98.8% of the total coronavirus-related research 
articles over the study period. The productivity of the 50 sampled countries/regions is 
shown in Table S1. The distribution of CORD-19 papers by month and country from 
January 2018 to April 2020 is indicated in Fig. S3. 
 
5 https://ourworldindata.org/covid-cases. The dataset used in this study is downloaded on May 9th,2020. 
6 There are rumors on suspected cases earlier than November 1, 2019 at different places around the world. 
In this study, we only consider cases officially reported in mainstream media 
7 For scientists with several affiliations belonging to different countries, we take into account the country 
information of the affiliation listed as the first. 
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Measuring Scientific Novelty of Papers 
Bio-Entities Extraction 
Entities extracted from CORD-19 papers’ titles and abstracts are the basic 
elements used for calculating novelty scores of entity combination in each CORD-19 
paper and thus allow capturing the changes in the sampled countries’ novelty score of 
coronavirus research by month. We extract bio-entities from titles and abstracts of 
CORD-19 papers from January 1951 to April 2020 using PubTator Central (PTC),8 a 
web-based application that automatically tags the input text with standardized 
biological entities (7). As PTC has annotated entities for all the papers indexed by 
PubMed, for those CORD-19 papers that have PubMed IDs, we programmatically 
retrieved their annotations by submitting PubMed IDs, in batches of 100 to PTC. For 
those not having a PubMed ID, we first submitted the request with their abstracts and 
titles, in which entities will be annotated by PTC server, then retrieve the annotated files 
by submitting the session ID returned by the previously submitted request. 39,882 
unique bio-entities from 38,787 CORD-19 papers were identified by PTC and were 
automatically categorized into four types: species, disease, gene and chemical. The 
major reason why PTC fails to extract any entities from titles and abstracts of 33% 
CORD-19 papers is that terms in those papers’ titles and abstracts do not include any 
standardized bio-concepts detected by PTC. The distribution of entities extracted from 
CORD-19 papers by type is illustrated in Fig. S4.  
Measuring Papers’ Novelty Score using BioBERT 
Measuring Papers’ Novelty Score from the Perspective of Combinatorial Novelty 
Building on the knowledge recombination theory (8) and the perspective of 
combinatorial novelty (9, 10), an indicator that measures the degree of novelty to which 
knowledge entities are combined in a paper has been proposed. In medicine, these 
knowledge entities can be represented by biological entities (e.g., drug, disease, and 
gene) in publications. Innovative discoveries and creative ideas usually stem from the 
recombination of more distant and diverse sources (9, 11-13). Novelty is a 
recombination of pre-existing knowledge components in an atypical way (9, 13). The 
key idea of the entity-based approach proposed in this study is that two entities that are 
more distant in the preexisting knowledge base, i.e., 29 million PubMed articles, their 
combination is perceived more novel.  
Mapping Bio-entities into Contextual Embeddings using BioBERT 
To measure the novelty of entity combination of CORD-19 papers, we use 
BioBERT (Bidirectional Encoder Representations from Transformers for Biomedical 
 
8 https://www.ncbi.nlm.nih.gov/research/pubtator/ 
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Text Mining) to capture the distance between two bio-entities in each entity pair 
extracted from CORD-19 papers. BioBERT is a language model pre-trained on 
biomedical literature, PubMed articles (14). Following the structure of BERT by Devlin, 
Chang, Lee and Toutanova (15), BioBERT consists of multi-layer bi-directional 
transformers and is pre-trained by masked language model and next sentence prediction 
tasks. BioBERT can generate a contextual representation for biomedical corpora, which 
allows different embeddings for the same word in different contexts, instead of 
producing context-independent word embeddings like Word2Vec (16) or GloVe (17) 
does. BioBERT has 13 hidden layers. The first layer, also known as input embedding 
or sub-word embedding layer, is the sum of token embeddings that are obtained from 
the WordPiece tokenizer (18), the segmentation embeddings and the positional 
embeddings. The last layer is the contextual (sub-word) representations (token-level). 
BioBERT has five versions (14),9 among which we use the version of BioBERT-
Base v1.1 that is pre-trained on PubMed 29 million articles with titles and pre-trained 
for one million steps based on BERT-base-Cased with the same vocabulary. The batch 
size for this model is set to 32 and the maximum sequence length is set to 32 tokens. In 
the former stage, we recognized bio-entities using PubTator and generated entity pairs 
from CORD-19 papers. We generate a sub-word representation for each bio-entity 
extracted from CORD-19 papers. The pipeline is shown in Fig. S5. Then we calculate 
bio-entities’ distance between the two sub-word representations for each bio-entities 
pair generated from CORD-19 papers.  
In Fig. S5, entity n is segmented by the WordPiece tokenizer (18) into a sequence 
of sub-words to mitigate the out-of-vocabulary (OOV) problem. (CLS) is added at the 
beginning and (SEP) is added at the end of, and get sub-words S={𝑆𝐶𝐿𝑆, 𝑆1, 𝑆2, ..., 𝑆𝑖, 
𝑆𝑆𝐸𝑃 .. For example, Entity “coronaviruses” is transformed into “(CLS) 
Co##rona##virus##es (SEP)”. The segmented entity S is then fed into the BioBERT. 
We use the last layer of BioBERT as the contextual representation, which generates a 
sequence of sub-word representations V in 𝑅𝑑 ×(𝑖+2)   where d denotes the 768 
dimensions of a hidden layer in BioBERT and i indicates the number of tokens except 
CLS and SEP for entity n. For instance, for the entity of “coronaviruses”, the model 
generates a vector, with 6 × 768 dimensions. The sub-word representations of CLS 
and SEP are ignored and the rest of the sequence of sub-word representations V are fed 
into average pooling that is used to calculate the average for each patch of the feature 
map with the kernel size of (number of tokens, 1) to get the final vector V in 𝑅𝑑  . Based 
on the embedding of bio-entities extracted from CORD-19 papers, we calculate the 
cosine distance defined in Equation 1 between two resulting vectors corresponding to 
each entity in an entity pair extracted from CORD-19 dataset 
𝑐𝑜𝑠𝑖𝑛𝑒 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒𝑖,𝑗 = 1 −
𝑖 ∙ 𝑗
‖𝑖‖2 ‖𝑗‖2
 (1) 
Where 𝑖 and 𝑗 indicate two entities in an entity pair; 𝑖 ∙ 𝑗 refers to the dot 
product of 𝑖 and 𝑗 ; ‖𝑖‖2 ‖𝑗‖2 means the product of 𝑖 's Euclidean norm and 𝑖 's 
Euclidean norm. 
 
9 https://github.com/dmis-lab/biobert. 
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Calculating Papers’ Novelty Score 
We extract 39,882 unique bio-entities using Pubtator Central from titles and 
abstracts of CORD-19 papers published from January 1951 to April 2020 and pair them 
up (i.e., 𝐸1 − 𝐸2, 𝐸1𝐸3, … ). The cosine distance of two entities in each of 596,495 
entity pairs detected in CORD-19 paper is captured from the resulting embedding using 
BioBERT that is pre-trained on 29 million PubMed articles. The distribution of the 
distance between two entities in entity pairs extracted from CORD-19 papers is shown 
in Fig. S6(A). We consider an entity pair in which the distance of two entities is in the 
upper 10th percentile of this distribution as a novel entity combination. The novelty 
score for each paper is measured by the proportion of novel entity pairs according to 
our definition of novelty entity combination to the possible number of entity pairs in a 
paper. The formula used to calculate the novelty score for a paper is shown in Equation 
2. 
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒𝑖 =
𝑚
𝐶𝑛2
 (2) 
where 𝑖 denotes paper 𝑖; 𝑛 indicates the number of bio-entities extracted from 
paper 𝑖; 𝐶𝑛
2 refers to the number of combinations of two that can be drawn from the 
set of n bio-entities extracted from paper 𝑖, i.e., the number of entity pairs generated 
by n bio-entities; 𝑚 denotes the number of entity pairs in which two entities’ distance 
is in the upper 10th percentile of the distribution of the distance of two entities in all 
entity pairs generated from CORD-19 papers. For example, for a paper that contains 
three bio-entities (i.e., entity a, b and c), the number of entity pairs for this paper is 
three. If the distance between a and b is in the upper 10th percentile of the distribution 
shown in Fig. S6(A), the novelty score for this paper is 1/3. 
The higher the novelty score, the more novel entity combination in a paper. The 
distribution of CORD-19 papers’ novelty scores is indicated in Fig. S6(B), suggesting 
that most of CORD-19 papers include no novel entity combination. 
Variables and Methods 
Variables 
This study investigates the relationship between the country-level monthly change 
in scientific novelty regarding entity combination of coronavirus papers and the 
occurrence of the first COVID-19 case in the country in a given month from January 
2018 to April 2020.  
The major independent variable is whether the first case of COVID-19 (COVID19) 
has been confirmed in the country by the month. We identify the month when the first 
case of COVID-19 is officially confirmed in each of 50 sampled countries according to 
the patient data from the website of Our World in Data. For example, China is the 
country where the first case of COVID-19 in the world was found in December 2019, 
followed by the US (Jan 2020), the UK (Jan 2020) and so forth. Once the first COVID-
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19 case has been confirmed in the country, the country gets treated in the month and the 
succeeding months. The distribution of treated countries (i.e., the countries where the 
first COVID-19 case has been confirmed) and untreated countries (i.e., the countries 
where the first COVID-19 case has not been confirmed) by the month is indicated in 
Fig. S7, suggesting that for most of the sampled countries, the first case was detected 
in either Jan 2020 or Feb 2020. All sampled countries have been exposed to COVID-
19 by the end of the study period.  
Paper-level variables: The way to generate the novelty score of each paper is 
explained in the section of Measuring Papers’ Novelty Score using BioBERT and the 
formula to calculate a paper’ novelty score is shown in Equation 2. Besides papers’ 
novelty scores, we are also interested in the change of papers’ parachuting collaboration 
ratio and international collaboration before and during the pandemic. Parachuting 
collaboration is defined as a co-authorship in which two authors never collaborated in 
the past. Parachuting collaboration ratio for a paper indicates the fraction of author 
pairs where two authors did not collaborate in the past to the total number of author 
pairs in a paper, measuring the degree to which parachuting collaboration is involved 
in the team, which is defined in Equation 3 
𝑃𝑎𝑟𝑎𝑐ℎ𝑢𝑡𝑖𝑛𝑔 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜𝑖 =
𝑝
𝐶𝑛2
 (3) 
where 𝑖 denotes paper 𝑖; 𝐶𝑛
2 refers to the number of combinations of two that 
can be drawn from the set of 𝑛 authors listed in paper 𝑖; 𝑝 indicates the number of 
author pairs in which two authors have no prior collaboration. The higher the 
parachuting collaboration ratio for a paper, the more parachuting collaboration involved 
in the team of the paper. 
International collaboration for a paper is a binary variable that is determined by 
whether authors listed in a paper are from at least two countries. It is one if at least two 
authors are from different countries, and zero otherwise.  
We also calculate team size for each paper defined as the number of authors listed 
in a paper as a control for papers’ novelty score, since team size is considered an 
influential factor of scientific novelty from prior literature (10, 19-21).  
Country-level variables: All paper-level variables need to be aggregated to the 
country level since this study examines the relationship between countries’ scientific 
novelty and the occurrence of the first COVID-19 case in the country. Based on a full 
counting method (1, 6), we use an example to demonstrate how paper-level variables 
are calculated to country-level variables. As shown in Fig. S8, there are two papers, P1 
by five authors from three countries (i.e., C1, C2 and C3), and P2 by three authors from 
two countries (C2 and C3), respectively. A1 who is an author of P1, and A2 who is in 
the author lists for P1 and P2, both belong to the country, C1. We generate a vector, 
{𝑣11, 𝑣12,…, 𝑣1𝑛., for P1, and a vector, {𝑣21, 𝑣22,…, 𝑣2𝑛., for P2. The element in 
the vector represents a variable for a paper, such as paper’s novelty score (𝑣𝑖1 ), 
parachuting collaboration ratio ( 𝑣𝑖2 ), whether or not the paper is internationally 
collaborative (𝑣𝑖3) and team size (𝑣𝑖4). For example, 𝑣11 and 𝑣21 indicate novelty 
score for P1 and P2, respectively. C1’s average novelty score is the sum of 𝑣11, 𝑣11 
and 𝑣21 weighted by the unique number of author-paper pairs (i.e., A1-P1, A2-P1 and 
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A2-P2), three. Similarly, C3’s average novelty score is equal to the sum of 𝑣11, 𝑣11 
and 𝑣21 weighted by the unique number of author-paper pairs (i.e., A4-P1, A5-P1 and 
A6-P2), three. The country-level versions for the remaining three paper-level variables 
are shown in the table in Fig. S8. 
The dependent variable is a country’s average novelty score (novelty score) of 
entity combination for papers by this country published in a given month, which 
quantifies the monthly average extent to which entities are combined rarely for 
knowledge production of the country. The higher the novelty score, the more novel 
countries’ knowledge production in a month. 
We are also interested in the association between new COVID-19 cases and deaths, 
and countries’ scientific novelty. Therefore, the daily numbers of new COVID-19 cases 
(COVID19 case) and deaths (COVID19 death) confirmed in each sampled country are 
aggregated to the month level and considered two explanatory variables. 
Various characteristics of scientific teams might be related to novelty, such as team 
size (19, 20), international collaboration (10) and collaboration of two authors who have 
not worked with each other before (22). To control these influential factors, the 
following control variables are introduced to the model. The country’s monthly average 
number of authors in CORD-19 papers is used to measure the average team size (team 
size) of coronavirus papers in a country. The proportion of internationally collaborative 
papers in a country in a given month is used to reflect the degree to which the papers 
are internationally collaborative (international collaboration ratio). The country’s 
average parachuting collaboration ratio (parachuting collaboration ratio) is used to 
measure the extent to which parachuting collaboration is involved in teams for CORD-
19 papers published in the month. 
Summary statistics of variables and the correlation matrix across variables are 
shown in Tables S2 and S3, respectively. 
Method: a Difference in Differences Strategy 
We use the unexpected outbreak of COVID-19 as a natural experiment to explore 
how scientific novelty evolves before and during the pandemic by using a difference in 
differences approach based on the data on 50 sampled countries over 28 months from 
2018 January to 2020 April. Our major goal is to estimate the association between the 
countries’ monthly average novelty scores of entity combinations for all papers 
published in a given month and whether the first COVID-19 case in a country has been 
confirmed by that month.  
To estimate the potential impact of the outbreak of COVID-19 in the country on 
scientific novelty of entity combination, we regress the dependent variables, i.e., 
novelty score, on whether the first case of COVID-19 in the country (COVID19) has 
been confirmed by the month and other covariates that might influence scientific 
novelty as shown in Equation 4. We apply an OLS linear model that contains fixed 
effects for country, 𝜃𝑖, those for month, 𝛿𝑡, to control the time-invariant and country-
invariant factors. The coefficient on COVID19 is a before-after estimate of the impact 
of the pandemic on scientific novelty.  
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𝑁𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒𝑖,𝑡 = 𝛼 + 𝛽𝐶𝑂𝑉𝐼𝐷19𝑖,𝑡 + 𝛾𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑖,𝑡 + 𝛿𝑡 + 𝜃𝑖 + 𝜀 (4) 
 
To investigate the dynamic effect of the outbreak of COVID-19 in the country on 
countries’ novelty, we introduce a set of dummies variables that reflect the timing of 
the occurrence of the first cases. If the outbreak of COVID-19 in month t truly impacts 
countries’ novelty, we expect to find the effect coming solely after the first cases are 
confirmed with similar patterns of change for the treatment and control groups before 
the first cases are detected. Following (23), we test this by replacing COVID19 in 
Equation 4 by a set of dummies variables that relate countries’ novelty score to the 
outbreak of COVID-19 in the prior, current and succeeding years: 
 
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒𝑖,𝑡 = 𝛼 + ∑ 𝑇 − 𝑛𝑛=1 + 𝑇0𝑖 + ∑ 𝑇 + 𝑛𝑛=1 + 𝛾𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑖,𝑡 + 𝛿𝑡 +
𝜃𝑖 + 𝜀 (5) 
 
Where T0 refers to the month when the first case is confirmed: T-n indicates 
whether the observation occurs n month(s) before the month of the first case; and T+n 
represents whether the observation occurs n month(s) after the month of the first case. 
The outbreak of the COVID-19 that causes an effect in a given month can be effective 
in T0 or later years, but it cannot have an impact before the month of the outbreak. 
Controls include variables that might be related to scientific novelty: countries’ monthly 
average parachuting collaboration ratio, the fraction of internationally collaborative 
papers by the country in the month, the average team sizes of papers by the country in 
the month and countries’ monthly productivity in coronavirus research. 
Similarly, using the DID strategy, we investigate the association between countries’ 
parachuting collaboration ratio in the month/the fraction of internationally collaborative 
papers by the country in the month and the outbreak of the COVID-19 in the country. 
The fixed effects of countries and months are included. 
To explore the relationship between the severity of COVID-19 in the country and 
the country’s novelty score, we regress the country’s average novelty score in the month 
on the monthly number of new COVID-19 cases and deaths. Control variables are the 
same with those in Equation 4. Fixed effects of country and month are included. 
Sub-sample Analyses and Regression Analyses including Interaction Terms 
By conducting sub-sample analyses and regression analyses including interaction 
terms, we investigate the association between the occurrence of the first global COVID-
19 case and papers’ novelty score, as well as the relationship between papers’ novelty 
score and two collaboration patterns (i.e., papers’ parachuting collaboration ratio and 
whether the paper is internationally collaborative) at the paper level in the normal 
science period and during COVID-19. The association between papers’ novelty scores 
and the occurrence of the first global COVID-19 case is estimated by Equation 6: 
 
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒𝑖 = 𝛼 + 𝛽1 𝐶𝑂𝑉𝐼𝐷19 + 𝛽2 𝑝𝑎𝑟𝑎𝑐ℎ𝑢𝑡𝑖𝑛𝑔 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 +
𝛽3 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 + 𝛽4𝑡𝑒𝑎𝑚 𝑠𝑖𝑧𝑒 + 𝛿𝑡 + 𝜀 (6) 
 
Page 19 of 38 
 
 
Where i denotes a paper; novelty score indicates the proportion of entity pairs that 
are highly distant to the possible entity pairs in a paper; COVID19 is a binary variable 
that is one if the paper is published in and after December 2019, and zero otherwise; 
parachuting ratio indicates the proportion of author pairs in which two authors have no 
prior collaboration in the past to the possible author pairs in a paper; international 
collaboration is a binary variable that is one if the team includes authors from at least 
two countries, and zero otherwise; team size indicates the number of authors listed in a 
paper; fixed effects regarding papers’ publication year (𝛿𝑡) is included; to explore the 
relationship between parachuting/international collaboration and papers’ novelty score 
before and during the COVID19, the interaction terms between 
parachuting/international collaboration ratio and the occurrence of the outbreak of 
COVID-19 are introduced to the model, i.e., 𝑝𝑎𝑟𝑎𝑐ℎ𝑢𝑖𝑛𝑔 × 𝐶𝑂𝑉𝐼𝐷19 , and 
𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 × 𝐶𝑂𝑉𝐼𝐷19. 
Sub-sample analyses are conducted to confirm the relationship between papers’ 
novelty score and two collaboration patterns before and during the pandemic by 
separating all coronavirus papers into two groups, with papers published before the 
occurrence of the first global COVID-19 case, i.e., December 2019, and those published 
after that month. Then, we estimate the relationship between papers’ novelty and two 
collaboration patterns based on these two groups of papers, separately.  
The Relationship between Papers’ Novelty Scores/Teams’ Characteristics and Citations. 
We explore the association between paper’s novelty scores and citations the paper 
received in a two-year (citation_2), five-year (citation_5), ten-year citation (citation_10) 
window and whether or not the paper is the top 1% highly cited papers (top1% citation) 
among the papers published in the same year. CORD-19 articles are linked to their 
versions in Microsoft Academic Graph dataset (MAG) according to papers’ DOI and 
PubMed ID. MAG includes more than 220 million publication records and their 
metadata (e.g., DOI, title, journal/conference, keywords, fields/disciplines, abstract, 
authors and their affiliations, etc.), as well as the more than 1.41 billion citation 
relationships among them. We found that 32,316 CORD-19 papers get at least one 
citation.  
Equation 7 is used to estimate how papers’ novelty scores and teams’ 
characteristics are related to papers’ citations. 
𝐶𝑖𝑡𝑎𝑡𝑖𝑜𝑛𝑖 = 𝛼 + 𝛽1𝑛𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒 + 𝛽2 𝑝𝑎𝑟𝑎𝑐ℎ𝑢𝑡𝑖𝑛𝑔 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 +
𝛽3 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 + 𝛽4𝑡𝑒𝑎𝑚 𝑠𝑖𝑧𝑒 + 𝛿𝑡 + +𝜀 (7) 
Where i denotes a paper; citation indicates citation counts papers received in a 
two-year, five-year or ten-year citation window; novelty sore indicates the proportion 
of entity pairs that are highly distant to the possible entity pairs in a paper; parachuting 
collaboration ratio indicates the proportion of author pairs in which two authors never 
collaborated in the past to the possible author pairs in a paper; international 
collaboration is a binary variable that is one if the team includes authors from at least 
two countries, and zero otherwise; team size indicates the number of authors listed in a 
paper; Fixed effects regarding papers’ publication year is included. The equation is 
estimated by ordinary least squares regression models (OLS). 
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The results are shown in Table S4. Papers’ novelty scores are insignificantly 
negatively related to citations of papers in different time windows, and whether the 
paper is the top 1% receivers of citations among papers published in the same year. This 
result suggests that papers in which entity combinations are novel are not “useless” 
papers, i.e., papers that are less cited. Besides, papers’ parachuting collaboration ratio, 
and whether the paper is international collaborative are significantly negatively related 
to citations papers received, irrespective of the length of the citation window. Papers’ 
team size is significantly positively correlated to citations of papers. 
Robustness Check 
We use multiple strategies to confirm the major findings of this study. First, we 
change to the 95th percentile as the threshold of the location of the distance between 
two entities in a novel entity pair discard bio-entities that appeared less than five times 
in CORD-19 papers, and conduct all the analyses.  
72.07% of bio-entities only appear once in CORD-19 papers, and the inclusion of 
bio-entities with a small frequency might make the distance between entities unreliable. 
We discard bio-entities with a total frequency lower than five, with 121,615 entity pairs 
remaining. We still use the BioBERT model pre-trained on 29 million PubMed articles 
to calculate the distance between entities for each entity pair obtained. Besides, we use 
the 95th percentile as the threshold of the location of the distance between two entities 
in a novel entity pair. Generally, we obtain consistent results shown in Tables S5 to S7. 
Related Work 
Scientific Community under Disasters 
Most studies on science of science assume that the system operates under the 
condition of institutional stability. The current studies on the scientific community are 
restricted to the framework of “normal science” (24) which is analogous to a gradually 
evolving ecological system proposed by Charles Darwin. But what would the scientific 
community react if the stable social and institutional conditions are punctuated by 
unexpected and exogenous events, such as natural or human-made disasters? The on-
going COVID-19 pandemic leads to significant disruptions on every aspect of economy 
and society, while little is known about whether and how extreme events or shocks, 
such as pandemics, reshapes the scientific community and scientific production, 
especially collaboration and innovation, as well as the nature and magnitude of this 
impact.  
Most studies that evaluate disasters mainly focus on the impacts on economy (25, 
26), politics, public health system (27, 28), psychology (29, 30), human life, social 
infrastructure, environment (31) and so forth. As an important component of society, 
science should be also impacted, whereas how science responds to disasters remains 
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open. The outbreak of the COVID-19 pandemic stimulates the emerging studies on this 
topic, while neither survey-based research nor studies that focus on the short-term effect 
of a particular event (32, 33) fails to capture an overview landscape of the effect of 
pandemics on science in the long run. 
There is a lack of understanding of how disasters influence collaboration and 
innovation, with only a few studies providing initial evidence on both disruptive and 
positive changes in research productivity after disasters. On the one hand, disasters 
increase knowledge production linked to the disaster (34, 35) and lead to changes in 
research topics. On the other hand, evidence shows a negative impact of disasters on 
research outside the related topics. A recent study shows the expansion of knowledge 
related to the disaster after the Fukushima Daiichi accident (35). The analysis of 
terrorism studies from 1991 to 2011 presents a positive relationship between the 
occurrence of terrorism events and productivity in the domain, with a declining trend 
of this productivity (35). This study also indicates after the 9/11 attacks, the terrorism-
related academic literature has grown substantially in the US. However, using the data 
on 107 journals in material science, Magnone (32) find the number of submitted papers 
and the number of contributing authors in the areas affected by disaster decrease 
immediately after Japan’s triple disaster. An analysis of the evolution of research topics 
pertaining to the Chernobyl accidents suggests that disasters could generate new 
scientific trends by motivating scientists to identify the important research problems 
caused by the disaster that requires solutions (33). Specifically, in the early years 
following the disaster, publications tend to address research questions in biochemistry, 
genetics and molecular biology, while the topics change to humanity- and environment-
related topics in later years (33). A recent survey including 4,500 PIs in the US and 
European countries shows how scientific workforce is affected by the outbreak of the 
COVID-19, as well as how research output is influenced in the near future (36). This 
survey finds a dramatic decline in time spent on research on average, especially on 
laboratory-based research after the onset of the pandemic with significant 
heterogeneities due to differences in fields, genders and individual characteristics. 
Another strand of the literature shows that the structure of scientific collaboration 
is impacted by disasters in both directions. With several exceptions, most literature 
provides descriptions of collaboration patterns after the disasters, failing to show a 
comparison between pre- and post-disaster periods (33, 35, 37). A study found that 
scientific teams become more collaborative and more productive with new 
collaborative relationships developed following natural disasters (38). However, a 
recent study reveals smaller-sized teams on coronavirus-related research during the 
pandemic relative to those before the outbreak of the COVID-19 (1). This study also 
indicates scientific teams with fewer nations, despite an increasing level of 
collaboration between China and the US. 
Existing Approaches that Measure Scientific Novelty 
As one aspect that reflects the core value in science, creativity or novelty is of 
great importance for scientific progress (39-41). Innovation is highly recognized in the 
research system and is often associated with critical criteria based on which decisions 
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of funding allocation, hiring, promotion and scientific awards are made (42). Because 
of its significant importance, extensive efforts have been made to measure the degree 
to which a scientific discovery provides unique knowledge that is unavailable from 
prior studies, and explore factors that influence the creation of innovation. 
In the early years, novelty is often evaluated through peer reviews or surveys (43-
45), which is practical only on a small scale. The development of computing power and 
enriched bibliometric data encourage the advancement in measuring various aspects of 
scientific discoveries including novelty. The first approach considers novelty as the 
degree to which scientific discovery is reused by subsequent literature regardless of the 
intrinsic quality of the study (12). Therefore, it is argued that citations could be a 
measure of usefulness and thus a proxy for creativity (46). Integrating the quality aspect 
of research articles, the second approach focuses on either the newness or the diversity 
of knowledge, with the first one related to the introduction of a new concept or objective 
in a study, and another linked to a broader range of knowledge embedded in research. 
For example, the novelty of a life sciences study is measured based on the age of 
keywords assigned to the article, which captures the extent to which a scientist’s work 
is novel relative to the world’s research frontier (47). In the field of biochemistry, 
another strategy to measure novelty is based on the introduction of a new chemical 
entity in research (48). The second strategy that focuses on the quality of scientific 
discovery is to measure the diversity of technological domains a patent cites using 
Herfindahl-type index of patent class cited by the focal patent (49, 50).  
The combinatorial perspective of novelty is often applied in measuring scientific 
novelty or originality. Novelty in science, technology and artistic creation, is often 
conceptualized as recombination of antecedent knowledge elements in an atypical way 
(9, 13, 51-54), which has become standard in the study of innovation. For example, 
according to Schumpeter (55), “innovation combines components in a new way, or that 
it consists in carrying out new combinations.” From Nelson and Winter (51), the 
creation of novelty in various fields ranging from art, science to practical life, is a result 
of the recombination of pre-existing conceptual and physical materials. An invention is 
considered as either a new combination of components or a new relationship between 
previously combined components (56). Building upon the perspective of combinatorial 
novelty, some researchers view novelty as a new or unusual combination of pre-existing 
knowledge components that could be operationalized by patent classes (13), keywords 
(57, 58), referenced articles (59, 60), referenced journals (9, 11) and chemical entities 
(48).  
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Fig. S1. The distribution of papers per year and by country in CORD-19 dataset from January 
1951 to April 2020. 
 
 
 
 
Fig. S2. The global distribution of COVID-19 cases and deaths by month.  
Data source: https://ourworldindata.org/covid-cases. This dataset is downloaded on May 9th,2020. 
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Fig. S3. The distribution of papers per month and by country in CORD-19 dataset from 
January 2018 to April 2020. The number in X-axis in fig (A) indicates n month(s) since January 
2018. For example, 24 indicates December 2019, when the first global COVID-19 case is officially 
confirmed. 
 
 
 
Fig. S4. The distribution of entities extracted from CORD-19 papers’ titles and abstracts from 
January 1951 to April 2020 by type and the top five entities in each type. 
 
 
Fig. S5. The pipeline of generating sub-word representation for each bio-entity extracted from 
CORD-19 papers using BioBERT. 
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Fig. S6. The distribution of the distance between two entities in entity pairs in CORD-19 
papers and that of CORD-19 papers’ novelty scores. The Y-axis indicates the frequency. 
 
 
Fig. S7. The distribution of treated countries and untreated countries by month.  
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Fig. S8. An example demonstrating the procedure to aggregate four paper-level variables to 
the country level. The element in the vector represents a variable for paper 𝑖 , such as paper’s 
novelty score (𝑣𝑖1), parachuting collaboration ratio (𝑣𝑖2), whether or not the paper is international 
collaborative (𝑣𝑖3) and team size (𝑣𝑖4) 
 
 
 
Fig. S9. An example of calculating a paper’s novelty score. 𝑃 and 𝐸 indicate papers and 
entities respectively. The formula used to calculate the novelty score for a paper is shown in the 
following equation. 
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 𝑠𝑐𝑜𝑟𝑒𝑖 =
𝑚
𝐶𝑛2
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where 𝑖 denotes paper 𝑖 ; 𝑛 indicates the number of bio-entities extracted from paper 𝑖 ; 𝐶𝑛
2 
refers to the number of combinations of two that can be drawn from the set of n bio-entities extracted 
from paper 𝑖, i.e., the number of entity pairs generated by n bio-entities; 𝑚 denotes the number of 
entity pairs in which two entities’ distance is in the upper 10th percentile of the distribution of the 
distance of two entities in all entity pairs generated from CORD-19 papers. For example, for paper 
𝑃𝑖 that contains three bio-entities (i.e., 𝐸1, 𝐸2 and 𝐸3), the number of entity pairs for this paper 
is three. If the distance between 𝐸1 and 𝐸3 is in the upper 10
th percentile of the distribution of the 
distance of two entities in all entity pairs generated from 58,728 coronavirus-related research articles, 
the combination of 𝐸1 and 𝐸3 is considered novel and thus the novelty score for this paper is 1/3. 
The way to generate the novelty score of a paper is explained in the section of Measuring Papers’ 
Novelty Score using BioBERT. 
 
 
Fig. S10. The linear prediction of papers’ novelty score before and during COVID-19. The X-
axis in sub-figure (A) and (B) indicates the level of papers’ parachuting collaboration ratio and 
whether the paper is internationally collaborative, respectively. The Y-axis indicates the predicted 
novelty scores of papers for levels of variables in the X-axis before (the orange line) and during 
COVID-19 (the blue line) when all other covariates are set to their means. The shaded areas 
represent upper and lower bounds of 95% CIs. 
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Table S1. The productivity of the 50 sampled countries/regions and the timing when the first 
COVID-19 case is confirmed in the country. 
December 2019 January 2020 February 2020 March 2020 
China 16467 USA 13187 Brazil 1008 Turkey 236 
  UK 2688 Netherlands 933 Poland 182 
  South Korea 2370 Switzerland 696 South Africa 137 
  France 2109 Iran 489 Argentina 113 
  Italy 2071 Belgium 334 Portugal 105 
  Germany 1801 Israel 273 Hungary 86 
  Japan 1313 Egypt 264 Colombia 86 
  Canada 1271 Denmark 194 Bangladesh 69 
  Spain 1230 Mexico 180 Kenya 50 
  Australia 1090 Greece 170 Czechia 45 
  India 1008 New Zealand 124 Chile 38 
  Taiwan 754 Norway 123 Peru 31 
  Sweden 340 Austria 120   
  Thailand 245 Ireland 106   
  Finland 216 Nigeria 93   
  Singapore 206 Croatia 53   
  Malaysia 201 Pakistan 47   
  Vietnam 151     
  Russia 147     
  Philippines 21     
Notes: the numbers in the table indicates the total number of papers by countries during the January 
2018-April 2020 period. 
 
 
Table S2. Statistics summary of variables 
Variable Observations Mean Std. Dev. Min Max 
Novelty score 944 0.092 0.133 0 1 
COVID19 1,400 0.114 0.318 0 1 
COVID19 case 1,400 0.714 2.324 0 13.682 
COVID19 death 1,400 0.381 1.489 0 10.965 
Team size 1,152 2.26 0.445 0.693 4.108 
Parachuting collaboration ratio 1,089 0.826 0.122 0.028 1 
International collaboration ratio 1,160 0.54 0.334 0 1 
Productivity 1,158 2.825 1.354 0.693 7.961 
Notes: productivity, COVID19 case, COVID19 death and team size are logged transformed (log e). 
 
Table S3. Correlation matrix of variables 
 (1) (2) (3) (4) (5) (6) (7) (8) 
(1) Novelty score 1       
(2) COVID19 0.072** 1      
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(3) COVID19 case 0.123*** 0.856*** 1     
(4) COVID19 death 0.113*** 0.713*** 0.947*** 1    
(5) Team size 0.05 0.058* 0.087*** 0.093*** 1   
(6) Parachuting collaboration ratio 0.005 -0.092*** -0.107*** -0.102*** -0.015 1  
(7) International collaboration ratio 0.055* -0.009 0.037 0.049* 0.026 0.362*** 1 
(8) Productivity 0.037 0.182*** 0.252*** 0.274*** -0.081*** -0.284*** 0.261*** 
 
Table S4. The estimated relationship between papers’ novelty score and citations papers 
received. 
 
 (1) (2) (3) (4) 
 Citation_2 Citation_5 Citation_10 Top1% citation 
Novelty score -0.051 -0.020 -0.036 0.010 
 (0.061) (0.061) (0.062) (0.008) 
Parachuting collaboration ratio -0.239*** -0.211*** -0.212*** -0.002 
 (0.036) (0.037) (0.037) (0.005) 
International collaboration -0.086*** -0.083*** -0.085*** -0.002 
 (0.025) (0.026) (0.026) (0.003) 
Team size (log e) 0.040*** 0.040*** 0.038*** 0.002*** 
 (0.002) (0.002) (0.002) (0.000) 
Year fixed effect Y Y Y Y 
Constant 0.628 1.686** 2.721*** 0.495 
 (0.419) (0.689) (0.927) (0.355) 
Observations 13,307 13,307 13,307 13,307 
R-squared 0.130 0.276 0.362 0.027 
Notes: fixed effects regarding publication year are included; robust standard errors are in 
parentheses; ***, ** and * represent significance at the 1%, 5%, and 10% level. 
 
Table S5. The DID estimates of the relationship between the occurrence of the first COVID-
19 case in the country and countries’ novelty scores in the month when using the 95th percentile 
as the threshold of the location of the distance between two entities in a novel entity pair. 
 
 (1) (2) 
Variables Novelty score 
COVID19 0.021**  
 (0.010)  
Three months before the first case(t_3)  -0.003 
  (0.017) 
Two months before the first case(t_2)  0.004 
  (0.014) 
One month before the first case(t_1)  -0.011 
  (0.006) 
The month of the first case(t0)  -0.000 
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  (0.008) 
One month after the first case(t+1)  0.041** 
  (0.019) 
Two months after the first case(t+2)  0.024 
  (0.018) 
Three months after the first case(t+3)  0.028 
  (0.025) 
Parachuting collaboration ratio  0.009 
  (0.032) 
International collaboration ratio  -0.017 
  (0.046) 
Productivity (log e)  -0.000 
  (0.005) 
Team size (log e)  -0.010** 
  (0.005) 
Month fixed effects Y Y 
Country fixed effects Y Y 
Constant 0.067 0.067 
 (0.064) (0.065) 
Observations 834 834 
R-squared 0.093 0.098 
Notes: The independent variable in columns 1 is whether the first COVID-19 case in the country 
has been confirmed by the month; fixed effects regarding month and country are included; robust 
standard errors clustered by countries are in parentheses; ***, ** and * represent significance at the 
1%, 5%, and 10% level 
 
Table S6. The OLS estimates of the relationship between the logged number of new COVID-
19 cases and deaths in the country and countries’ novelty score in a month when using the 
95th percentile as the threshold of the location of the distance between two entities in a novel 
entity pair. 
 (1) (2) 
Variables   Novelty score 
COVID-19 case (log e) 0.005***  
 (0.002) 
 
COVID-19 death (log e)  0.006*** 
 
 (0.002) 
Parachuting collaboration ratio 0.006 0.007 
 (0.033) (0.033) 
International collaboration ratio 0.002 -0.009 
 (0.048) (0.045) 
Productivity (log e) -0.002 -0.001 
 (0.005) (0.005) 
Team size (log e) -0.010** -0.010** 
 (0.005) (0.005) 
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Constant 0.004 0.013 
 (0.064) (0.062) 
Month fixed effects Y Y 
Country fixed effects Y Y 
Observations 834 834 
R-squared 0.098 0.096 
Notes: The independent variables in columns 1 and 2 are the monthly logged transformed number 
of new COVID-19 cases and that of death, respectively; fixed effects country are included; robust 
standard errors clustered by countries are in parentheses; ***, ** and * represent significance at the 
1%, 5%, and 10% level. 
 
Table S7. The estimated relationship between papers’ novel scores and teams’ characteristics 
when using the 95th percentile as the threshold of the location of the distance between two 
entities in a novel entity pair. 
 
  (1) (2) (3) (4) 
 Novelty score 
Variables 
Papers published  
before COVID19 
Papers published  
during COVID19 All papers All papers 
Team size (log e) -0.002 -0.002 -0.002 -0.002 
 
(0.003) (0.013) (0.002) (0.002) 
International collaboration ratio 0.000 0.022 0.000 0.000 
 
(0.004) (0.014) (0.004) (0.004) 
Parachuting collaboration ratio -0.004 0.050** -0.004 -0.003 
 
(0.006) (0.025) (0.006) (0.006) 
COVID19 
  
-0.046** -0.023* 
   
(0.020) (0.013) 
Parachuting ╳COVID19 
  
0.055** 
 
   
(0.026) 
 
International╳COVID19 
   
0.024 
    
(0.014) 
Year fixed effect Y Y Y Y 
Constant 0.044*** -0.024 0.044*** 0.043*** 
 
(0.007) (0.035) (0.007) (0.007) 
Observations 12,059 378 12,437 12,437 
R-squared 0.000 0.007 0.000 0.000 
Notes: fixed effects regarding publication year are included; robust standard errors are in 
parentheses; ***, ** and * represent significance at the 1%, 5%, and 10% level
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Table S8. The DID estimates of the relationship between the occurrence of the first COVID-19 case in a country and countries’ novelty scores and two 
collaboration variables in the month. 
 
 
(1) (2)  (3) (4)  (5) (6) 
 
Novelty score  
Parachuting collaboration 
 ratio 
 International 
collaboration ratio 
COVID19 0.038*** 
 
 0.031*** 
 
 -0.092*** 
 
 
(0.011) 
 
 (0.010) 
 
 (0.024) 
 
Three months before the first case(t_3) 
 
0.015  
 
0.034**  
 
-0.048 
  
(0.021)  
 
(0.015)  
 
(0.050) 
Two months before the first case(t_2) 
 
-0.017  
 
0.007  
 
-0.036 
  
(0.020)  
 
(0.018)  
 
(0.059) 
One month before the first case(t_1) 
 
-0.002  
 
0.022  
 
-0.022 
  
(0.014)  
 
(0.025)  
 
(0.052) 
The month of the first case(t0) 
 
-0.014  
 
0.012  
 
-0.028 
 
 
(0.015)  
 
(0.019)  
 
(0.046) 
One month after the first case(t+1) 
 
0.048***  
 
0.030  
 
-0.124*** 
 
 
(0.018)  
 
(0.020)  
 
(0.041) 
Two months after the first case(t+2) 
 
0.063**  
 
0.038**  
 
-0.125*** 
 
 
(0.026)  
 
(0.018)  
 
(0.039) 
Three months after the first case(t+3) 
 
0.124***  
 
0.065***  
 
-0.142*** 
  
(0.045)  
 
(0.021)  
 
(0.048) 
Productivity (log e) -0.005 -0.012  
  
 
  
 
(0.010) (0.011)  
  
 
  
team size (log e) 0.040* 0.042**  
  
 
  
 
(0.021) (0.021)  
  
 
  
Page 33 of 38 
 
 
parachuting collaboration ratio 0.042 0.030  
  
 
 
 
 
(0.048) (0.047)  
  
 
  
international collaboration ratio 0.008 0.006  
  
 
  
 
(0.020) (0.019)  
  
 
  
Month fixed effects Y Y  Y Y  Y Y 
Country fixed effects Y Y  Y Y  Y Y 
Constant -0.030 -0.000  0.822*** 0.820***  0.553*** 0.557*** 
 
(0.057) (0.054)  (0.001) (0.002)  (0.003) (0.006) 
Observations 919 919  1,089 1,089  1,160 1,160 
R-squared 0.119 0.132  0.119 0.124  0.227 0.230 
 
Notes: The independent variable in columns 1, 3 and 5 is whether the first COVID-19 case in the country has been confirmed by the month; fixed effects regarding 
month and country are included; robust standard errors clustered by countries are in parentheses; ***, ** and * represent significance at the 1%, 5%, and 10% level 
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Table S9. The OLS estimates of the relationship between the logged number of new COVID-
19 cases and deaths in the country and countries’ novelty scores in a month. 
 
  (1) (2) 
Variables Novelty score 
COVID-19 case (log e) 0.008***  
 (0.002)  
COVID-19 death (log e)  0.009*** 
  (0.003) 
Productivity (log e) -0.011 -0.007 
 (0.011) (0.012) 
Team size (log e) 0.041* 0.039* 
 (0.021) (0.021) 
Parachuting collaboration ratio 0.032 0.036 
 (0.050) (0.049) 
International collaboration ratio 0.007 0.009 
 (0.020) (0.020) 
Country fixed effects Y Y 
Month fixed effects Y Y 
Constant -0.054 -0.062 
 (0.055) (0.055) 
Observations 919 919 
R-squared 0.126 0.121 
Notes: The independent variables in columns 1 and 2 are the monthly logged transformed number 
of new COVID-19 cases and that of death, respectively; fixed effects of country and month are 
included; robust standard errors clustered by countries are in parentheses; ***, ** and * represent 
significance at the 1%, 5%, and 10% level 
 
 
Table S10. The estimated relationship between papers’ novel scores and teams’ characteristics. 
 
 
(1) (2) (3) (4) 
 
Novelty score 
Sample 
Papers published  
before COVID19 
Papers published  
during COVID19 All papers All papers 
Team size (log e) 0.001 -0.008 0.001 0.001 
 
(0.002) (0.012) (0.002) (0.002) 
International collaboration ratio -0.001 0.036*** -0.001 -0.001 
 
(0.003) (0.008) (0.003) (0.003) 
Parachuting collaboration ratio -0.011** 0.081*** -0.011** -0.009* 
 
(0.005) (0.023) (0.005) (0.005) 
COVID19 
  
-0.081*** -0.040*** 
   
(0.023) (0.012) 
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Parachuting ╳COVID19 
  
0.095*** 
 
   
(0.024) 
 
International╳COVID19 
   
0.043*** 
    
(0.008) 
Year fixed effect Y Y Y Y 
Constant 0.002 -0.050* 0.002 0.002 
 
(0.004) (0.030) (0.004) (0.004) 
Observations 16,421 503 16,924 16,924 
R-squared 0.005 0.019 0.005 0.005 
 
Notes: fixed effects regarding publication year of papers are included; robust standard errors are in 
parentheses; ***, ** and * represent significance at the 1%, 5%, and 10% level. The direction of 
coefficient (-0.001, p>0.1 in column 1 of Table S10) on international collaboration ratio on novelty 
score for papers published before COVID-19 is opposite to that (0.036, p<0.01 in column 2 of Table 
S10) for papers published during COVID-19. Furthermore, the coefficient (-0.011, p<0.01 in 
column 1 of Table S10) of parachuting collaboration ratio on novelty score is significantly negative 
for papers published in the normal science period, whereas it (0.081, p<0.01 in column 2 of Table 
S10) becomes significantly positive for papers published during the pandemic. 
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